Home  /  Resource Library  /  EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS OF THE SADAL STUDY

EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS OF THE SADAL STUDY

EHA 2020: Results of a phase II study investigating selinexor for the treatment of relapsed DLBCL.